MedTrace Logo

Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis

NCT02453997 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2024-12-12

No results posted yet for this study

Summary

This study investigate mycophenic acid (MPA) pharmacokinetics and pharmacogenomics and their impact on the clinical outcomes in lupus nephritis (LN) patients. Lupus nephritis patients (both active or inactive) will be recruited. MPA levels will be checked at 1, 2, 4, 8, 10, 12 hrs after MMF administration by an enzymatic assay upon recruitment, then at 6-months' intervals and also when clinically significant events occurred. The MPA levels will be correlated with clinical parameters and outcomes. Pharmacogenomics studies will also be carried out and correlated with MPA exposure and clinical outcomes.

Conditions

Sponsors & Collaborators

  • United Christian Hospital

    collaborator OTHER

  • The University of Hong Kong

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2019-04-17
Completion
2019-04-17

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453997 on ClinicalTrials.gov